Medical Therapy for HFrEF - Early Benefit from Synergies and a Personalised Approach

Article Cardiac & Cardiovascular Systems

Accelerated and personalized therapy for heart failure with reduced ejection fraction

Li Shen et al.

Summary: Previous guidelines for treating heart failure with reduced ejection fraction recommended initiating therapy in a chronological order based on trial history. However, this study suggests that accelerating treatment titration and optimizing treatment ordering may improve patient outcomes.

EUROPEAN HEART JOURNAL (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry

Domenico D'Amario et al.

Summary: Heart failure patients with reduced ejection fraction who use higher doses of RASi or ARNi and beta-blockers have a lower risk of cardiovascular death or HF hospitalization. Patients using two drug classes at 50%-99% of the target dose have a lower risk compared to using one drug class at 100% of the target dose.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Adriaan A. Voors et al.

Summary: The sodium-glucose cotransporter 2 inhibitor empagliflozin improves clinical outcomes in patients hospitalized for acute heart failure, regardless of ejection fraction or the presence of diabetes.

NATURE MEDICINE (2022)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

Heart failure drug treatment: the fantastic four

Johann Bauersachs

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Deepak L. Bhatt et al.

Summary: In patients with diabetes and recent worsening heart failure, treatment with sotagliflozin significantly reduced the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure compared to placebo, regardless of the timing of administration.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology

Giuseppe M. C. Rosano et al.

Summary: Implementation of treatment in heart failure is hindered by poor tolerability and renal function issues, leading to difficulty in reaching target drug doses. A personalized approach to therapy based on patient profiles may be more effective than traditional forced titration of each drug class.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems